AstraZeneca, Mylan, Osmotica Pharmaceuticals Corp., Par Pharmaceutical, Torrent neurology news
The U.S. District Court for the District of New Jersey ruled that a formulation patent covering atypical antipsychotic Seroquel XR quetiapine extended release from AstraZeneca is valid and infringed by ANDA submissions from four generics companies. AstraZeneca filed the infringement claims in 2010. The court said in its decision that the sustained release formulation claimed in U.S. Patent No. 5,948,437 is not obvious because it provides several benefits over immediate release quetiapine, including a superior sedation profile and significant improvement in the speed with which it can be titrated. The patent expires in 2017. U.S. Patent No. 4,879,288 covering the composition of Seroquel expired last September.
Defendants were Anchen Pharmaceuticals Inc., which was acquired by Par last year; Mylan; Osmotica; and Torrent. ...